Company news

Passage Bio, Inc. news in 2021

Passage Bio, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

December 16, 2021

Passage Bio Announces Pipeline Expansion and Clinical Program Update

December 7, 2021

Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

November 18, 2021

Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights

November 3, 2021

Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021

October 27, 2021

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

September 6, 2021

Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights

August 4, 2021

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

August 3, 2021

Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

July 28, 2021

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2021

Passage Bio Announces Key Executive Appointments

July 18, 2021

Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio

May 31, 2021

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

May 10, 2021

Passage Bio to Host Virtual R&D Event on May 17

May 9, 2021

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights

May 4, 2021

Passage Bio Partners with InformedDNA® to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia

May 2, 2021

Passage Bio to Report First Quarter 2021 Financial Results on May 5, 2021

April 28, 2021

Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease

April 4, 2021

Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

March 31, 2021

Passage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer

March 21, 2021

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

March 2, 2021

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

February 18, 2021

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

February 7, 2021

Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

January 27, 2021

Passage Bio Announces Pricing of Public Offering

January 20, 2021

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25

January 18, 2021

Passage Bio Announces Launch of Proposed Public Offering

January 18, 2021

Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021

January 10, 2021

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

January 3, 2021

Calls in 2021

Decks in 2021